Introduction
Lung cancer is the most common cause of cancer death worldwide [1] . More than 1.3 million people die of lung cancer each year. In the United States and Canada, more people die of lung cancer than breast, colon, and prostate cancers combined [2] . Former heavy smokers remain at an elevated risk for developing lung cancer even years after they stop smoking [3, 4] . Fifty percent of newly diagnosed lung cancer patients are former smokers [5] . Although antitobacco initiatives in young people are important in preventing lung cancer in the future, an additional lung cancer control strategy such as early detection besides smoking cessation is needed for individuals who are already at risk.
Screening has been shown to be effective in reducing the incidence and mortality of cancer of the cervix, breast, and colon. This is accomplished by detecting high-grade dysplasia and in-situ carcinomas. Previous efforts to use sputum and/or chest radiography to detect early lung cancer in the 1980s failed to demonstrate a reduction in lung cancer mortality [6] . This was probably the result of the rarity of malignant cells in expectorated sputum and the insensitivity of conventional chest radiography. New knowledge about the biology and molecular biology of lung cancer, however, as well as advances in imaging technologies, allow us to design more effective lung cancer screening strategies [7] .
What is the target lesion for screening?
To understand the potential advantages and limitation of newer screening methods, it is important to define the target lesions that we are trying to detect. A test that can detect advanced invasive lung cancer may not have the same performance in detecting preinvasive or microinvasive lung cancer.
Tumor size is an important prognostic indicator and is one of the fundamental parameters in the international TNM staging system. An important issue in early detection is the ability of a screening test to detect lung cancers that have not yet metastasized to regional lymph nodes or systemically to other organs. For superficial non-small cell lung cancers (NSCLCs) that are located in the central airways diagnosed by fiberoptic bronchoscopy with a negative chest radiograph or computed tomography (CT), surgical studies and follow-up studies of patients treated by photodynamic therapy or other endobronchial treatments showed that the incidence of lymph node metastases and the long-term cure rate correlate with the surface dimensions and characteristics of the tumor. When the surface diameter is greater than 1 cm 2 or when there is increasing nodularity of the tumor there is a greater tendency for the tumor to infiltrate deeper into the bronchial wall. Tumors that have extended beyond the cartilage layer have an increasing tendency to metastasize to regional lymph nodes or systemic sites [8,9 • ]. As a result, the cure rate of these so-called radiologically occult lung cancers after endobronchial therapy dropped from approximately 95% for tumors with a surface area of 1 cm 2 to about 46% for tumors $2 cm 2 [9 • ,10].
For peripheral lung cancers, several authors have published data on the metastatic potential of resected NSCLCs. For example, the incidence of regional lymph node involvement is related to the tumor size. These findings suggest that the goal of a screening test should be the detection of individuals harboring lung cancers that are #1 cm in diameter. With this in mind, it should not be surprising that previous screening studies using chest radiography failed to show a benefit, because many of the tumors were not discovered until they were 2 or 3 cm or larger. When lung cancers detected by low-dose screening spiral thoracic CT were reviewed, chest radiography failed to detect 77% of all CT-detected cancers, including 79% of the tumors #20 mm and 50% of the tumors more than 20 mm [18] . With the introduction of multidetector CT scanners and thin image slices, nodules #1 mm can now be detected. Advances in CT scanning technologies hold promise that more lung cancers can be detected in the subcentimeter stage that are amenable to curative therapy.
Gender differences in lung cancer
There has been some suggestion that women may be at higher risk from lung cancer than men with equivalent smoking history, but this remains a controversial issue. In a recent study of 2490 high-risk subjects undergoing screening thoracic CT for lung cancer, a significantly higher odds ratio for lung cancer in women compared with men was found [19] . On evaluation of the Nurses' Health Study and the Health Professionals Follow-up Study, however, no excess rates of lung cancer were found in women with comparable smoking histories [20 • ]. Women, however, were found to have a significantly higher risk of adenocarcinoma (HR 1.32) compared with men. In screening CT studies conducted in Japan, as many cases of lung cancer were found in women as in men [21] . Most women were nonsmokers. The tumors were mostly bronchioloalveolar carcinoma or well-differentiated adenocarcinoma. A significantly higher rate of mutation in the tyrosine kinase domain of the epidermal growth factor receptor gene and a better response to tyrosine kinase inhibitors such as gefitinib was found in nonsmoking Asian women with bronchioloalveolar carcinoma or adenocarcinoma compared with white North American subjects [22, 23] . Whether screening CT is more efficacious in women compared with men, especially in Asian countries, and the role of screening in nonsmoking Asian women require further studies.
Lung cancer screening with spiral computed tomography
The use of spiral CT in lung cancer screening studies has now been reported by a number of groups [24-33, Although spiral CT appears to be a promising screening tool, it has a number of potential limitations. The high sensitivity is associated with a low specificity because many noncancerous conditions can also show up as small noncalcified nodules. When the scanning protocol was changed from a single-detector CT scanner and 5 to 10-mm slice thickness to 16-detector scanners and a 1-mm slice thickness, the proportion of subjects found to have one or more lung nodules increased from approximately 30 Although volumetric measurements are still not yet reliable in determining growth of small nodules less than 5 mm, three-dimensional volumetric measurement of nodule growth provides a better understanding of the biologic behavior of early lung cancer. Although most CTdetected peripheral lung cancers have a doubling time from 50 to 350 days, some cancers appear to grow very slowly, with a doubling time of more than 2 years, making overdiagnosis possible if screening were applied to elderly individuals or to those with competing causes of mortality [44] [45] [46] [47] .
Screening with spiral CT alone results in a higher proportion of adenocarcinoma than the general population with lung cancer. Further information regarding differences in subsets of small subcentimeter peripheral adenocarcinoma and their radiologic, pathologic, and prognostic features are being reported, and the impact that this will have on curative surgical techniques discussed. The largest prognostic feature appears to be the amount of nonsolid or ground glass component on CT scan. A small nonsolid lesion with a more than 50% ground glass component has the best prognosis, and limited resections are being proposed for these lesions rather than complete lobectomy, although randomized trials have not yet been completed [13, [48] [49] [50] ,51 • ,52 • ]. Most of these data, however, come from screening studies performed in Japan, where approximately 50% of subjects screened are nonsmokers. These data may not be extrapolated to the smoking population because the biologic behavior and prognosis of adenocarcinoma may be quite different [53] . Further prospective evaluation of the biology of adenocarcinoma in smokers and the best method of surgical cure is required.
Using a combination of autofluorescence bronchoscopy and CT, a study at BCCA showed that 25% of the cancers detected were found to be CT occult [33, 36 • ]. All these cancers were in-situ or microinvasive squamous cell carcinomas in the central airways. Currently, screening CTscan alone does not detect these early curable cancers, and therefore may reduce the effectiveness of a screening program. In the Early Lung Cancer Action Project (ELCAP) study, two interval cancers were endobronchial and were missed on the baseline CT scan [24] . Most of these small superficial bronchial cancers can be cured by endobronchial therapy such as electrocautery or cryotherapy instead of surgery, with potential cost savings [54 • ]. In populations with a significant incidence of squamous cell carcinoma, it is important to evaluate the central airways to detect these lesions. The role and cost-effectiveness of autofluorescence bronchoscopy in a lung cancer screening program needs to be investigated further.
Potential harms from lung cancer screening such as risks of investigative procedures and radiation-induced lung cancer need to be considered. The lung dose from a single low-dose CT scan is 2.5 to 9.0 mGy, with corresponding increased total doses for repeat examinations. The estimated increase in lung cancer from annual CT radiation exposure over 25 years of screening is 1.8% of subjects screened (95% CI, 0.5-5.5) [55 • ].
Investigation and follow-up of computed tomography-detected lung nodules
A new computer-aided method of growth assessment is being developed using three-dimensional reconstruction images and volumetric analysis [44] . The earliest time growth can be reliably identified was found to be 12 months, 5 months, 3 months, and 1 month respectively for nodules 2 to 4 mm, 5 to 7 mm, 8 to 9 mm, and $10 mm found in baseline screening CT [56 An exciting development is the use of exhaled breath condensate to detect lung cancer with volatile organic compounds or molecular markers [63, 64 • ] Measuring oxidative stress products such as alkanes and monomethylated alkanes in exhaled breath, Phillips et al. [63] reported a sensitivity of 90% and specificity of 83% for detection of lung cancer. If the technology can be simplified and the chemicals separating cancer from noncancer patients better defined, it may have a role in screening because it can be incorporated as part of a spirometry testing. The potential of a breath, sputum, or blood biomarker as the first step in screening is that if we can identify individuals at highest risk of lung cancer, the positive predictive value of spiral CT or autofluorescence bronchoscopy will improve significantly when applied more selectively.
Conclusion
While waiting for the results of randomized clinical trials to evaluate the efficacy of spiral CT for lung cancer screening, rapid advances in imaging technologies allow detection of lung cancers at smaller size, assessment of growth rates, and sampling of these lesions with minimally invasive methods to understand the molecular biology of these early lesions. A better understanding of genetic susceptibility and the development of sputum, blood, or exhaled breath biomarkers will also allow more selective screening to improve cost-effectiveness.
